Financial Daily from THE HINDU group of publications
Wednesday, Mar 29, 2006


News
Features
Stocks
Shipping
Archives
Google

Group Sites

Corporate - Mergers & Acquisitions
Marketing - IPR


Biocon to acquire IP assets of Nobex Corp

Our Bureau

Bangalore , March 28

Biocon Ltd has announced that it has won the bid to acquire all intellectual property assets of its bankrupt US research partner Nobex Corp.

The IP acquisition, unprecedented among Indian companies, has cost Biocon $5 million, including the final bid amount of $4.1 million, royalties and creditor settlements in what could be called a not hotly contested bid.

The biotechnology major becomes the sole inventor of delivery technologies and processes for half a dozen pipeline drugs of Nobex. The two were working on global co-development and commercialisation of the revolutionary oral insulin tablet IN105 and a heart failure drug called BN054, both of them in advanced pre-clinical stages.

The other assets include Oratonin, an oral calcitonin in phase 1 trials for osteoporosis; Oral PTH (Para Thyroid Hormone) and APAZA, an oral small molecule drug in phase 1/2 trials for inflammatory bowel disease.

The products would be at least couple of years away and the potential returns from oral insulin alone could be huge, sources said.

Ms Kiran Mazumdar-Shaw, Biocon CMD, said, "This is truly a strategic acquisition which provides us with an immensely valuable IP platform. It also gives us full ownership of our ongoing oral insulin and oral BNP programmes. It also provides us access to additional innovative technologies and new therapeutic paradigms. We have acquired an intellectual property estate of nearly 300 patents and patent applications focussed on oral peptide therapeutics in the metabolic & cardiovascular segment. We propose to leverage these proprietary assets through a combination of licensing and co-development partnerships."

Related Stories:
Biocon makes $3.5 m pitch for Nobex IP
Biocon plans to acquire Nobex's IP assets

More Stories on : Mergers & Acquisitions | IPR | Bio-tech & Genetics | Overseas Investments

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
RNRL plans Rs 1,100-cr pref issue


Dhampur Sugar fixes GDR price at $4.81
Indian `John Doe' sued
ICSA product secures patent
Suryajyoti Spg converts warrants
Biocon to acquire IP assets of Nobex Corp
Universal Empire to invest Rs 1,750 cr
GAIL, HPCL seek level-playing field
Hindalco arm to raise funds
L&T ties up with Saudi Kanoo group
BSL, French co in tie-up
Nortel, Bharti sign 5-year services deal
Thomas Cook India looking at expansion
iGATE to expand footprint in India
Sanyo to increase presence in India
Bhai Mohan Singh: Pioneer of pharma



The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line